Large Inflow of Money Witnessed in Taro Pharmaceutical Industries Ltd.

Taro Pharmaceutical Industries Ltd. (TARO) : Thursdays money flow points at investors jumping to buy the stock on the weakness of price. $13.95 million worth of transactions were on upticks, whereas, the downticks accounted for $12.87 million worth of transactions. The net money flow was a positive $1.08 million and the uptick to downtick ratio was 1.08. The net money flow into the stock was $0 million. The lack of interest in trading on downticks shows that the investors dont want to sell their holdings. The upticks accounted for $0 million of the total block trades, indicating continued buying interest on weakness, which bodes well for the future of the stock. Taro Pharmaceutical Industries Ltd. (TARO) was trading at $139.75, down $5.29 during day. The stock slid -3.65% over the previous days close. For the week, the stock recorded -4.29% over the previous weeks close.


The stock has recorded a 20-day Moving Average of 2.16% and the 50-Day Moving Average is 0.1%.

Taro Pharmaceutical Industries Ltd. (NYSE:TARO): The stock opened at $145.25 on Thursday but the bulls could not build on the opening and the stock topped out at $146.35 for the day. The stock traded down to $139.24 during the day, due to lack of any buying support eventually closed down at $140.88 with a loss of -2.87% for the day. The stock had closed at $145.04 on the previous day. The total traded volume was 554,464 shares.

Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company develops, manufactures and markets prescription (Rx) and over-the-counter (OTC) pharmaceutical products, primarily in the United States, Canada and Israel. Taro also develops and manufactures active pharmaceutical ingredients (APIs), primarily for use in its finished dosage form products. The Companys primary areas of focus include semi-solids formulations, such as creams and ointments, and other dosage forms, such as liquids, capsules and tablets, primarily in the dermatological and topical, cardiovascular, neuropsychiatric and anti-inflammatory therapeutic categories. Taros owned product brands include Rokacet, Topicort, Etopan, Lustra and Ovide. Its other generic products include acetazolamide, amiodarone hydrochloride, ammonium lactate, calcipotriene, carbamazepine, cetirizine hydrochloride, ciclopirox olamine, clindamycin, clobetasol propionate and clomipramine hydrochloride.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.